Understanding the Hemostatic Effects of Recombinant Factor VIIa by Clot Waveform Analysis

Seminars in Hematology

Volumn 41, Issue 1 SUPPL. 1, 2004, Pages 125-131

  Shima, Midori ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 7; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE; PHOSPHOLIPID; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLOOD CLOTTING; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MEGADOSE; HEMOPHILIA A; HEMOSTASIS; HUMAN; LIGHT; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PRIORITY JOURNAL; THROMBOCYTE; THROMBOELASTOGRAPHY; WAVEFORM;

EID: 0842342599     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2003.11.021     Document Type: Conference Paper

References (26)

1. Al Dieri R, Peyvandi F, Santagostino E, et al: The thrombogram in rare inherited coagulation disorders: Its relation to clinical bleeding. Thromb Haemost 88:576-582, 2002
2. Bouma BN, Marx PF, Mosnier LO, et al: Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 101:329-354, 2001
3. Braun PJ, Givens TB, Stead AG, et al: Properties of optical data from activated partial thromboplastin time and prothrombin time assays. Thromb Haemost 78:1079-1087, 1997
4. Brinkhaus KM, Graham JB: Hemophilia and hemophilioid states. Blood 9:254-257, 1954
5. Camenzind V, Bombeli T, Seifert B, et al: Citrate storage affects thrombelastograph analysis. Anesthsiology 92:1242-1249, 2000
6. Erhardtsen E: Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost 26:385-391, 2000
7. Falati S, Liu Q, Gross P, et al: Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-Selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 197:1585-1598, 2003
8. Hardisty RM, Macpherson JC: A one-stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma. Thromb Diath Haemorrh 7:215-228, 1962
9. Hartert H: Blutgerninnungstudien mit der thromboelastographic, einen neven unteresuchingsver fahren. Klin Wochenschr 16:257-260, 1948
10. Hemker HC, Willems GM, Beguin S: A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 56:9-17, 1986
11. Hoffman M, Monroe DM 3rd: The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol 38:6-9, 2001 (suppl)
12. Hoffman M, Monroe DM, Oliver JA, et al: Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood 86:1794-1801, 1995
13. Kay MA, Manno CS, Ragni MV, et al: Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24:257-261, 2000
14. Kenet G, Lubetsky A, Luboshitz J, et al: A new approach to treatment of bleeding episodes in young hemophilia patients: A single bolus megadose of recombinant activated factor VII (NovoSeven®). J Thromb Haemost 1:450-455, 2003
15. Kyrle PA, Mannhalter C, Beguin S, et al: Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 18:1287-1291, 1998
16. Lakich D, Kazazian HH Jr, Antonarakis SE, et al: Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet 5:236-241, 1993
17. Macfarlane RG, Biggs R: A thrombin generation test: the application in haemophilia and thrombocytopenia. J Clin Pathol 6:3-8, 1953
18. Peake IR, Bloom AL, Giddings JC, et al: An immunoradiometric assay for procoagulant factor VIII antigen: Results in haemophilia, von Willebrand's disease and fetal plasma and serum. Br J Haematol 42:269-281, 1979
19. Rosen S, Andersson M, Blombäck M, et al: Clinical application of a chromogenic substrate method for determination of factor VIII activity. Thromb Haemost 54:818-823, 1985
20. Sarich TC, Eriksson UG, Mattsson C, et al: Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Thromb Haemost 87:300-305, 2002
21. Shima M, Matsumoto T, Fukuda K, et al: The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost 87:436-441, 2002
22. Sorensen B, Johansen P, Christiansen K, et al: Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 1:551-558, 2003
23. Sultan Y, Loyer F: In vitro evaluation of factor VIII-bypassing activity of activated prothrombin complex concentrate, prothrombin complex concentrate, and factor VIIa in the plasma of patients with factor VIII inhibitors: Thrombin generation test in the presence of collagen-activated platelets. J Lab Clin Med 121:444-452, 1993
24. Turecek PL, Varadi K, Keil B, et al: Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 33:16-22, 2003
25. Vig S, Chitolie A, Bevan DH, et al: Thromboelastography: A reliable test? Blood Coagul Fibrinolysis 12:555-561, 2001
26. Yoshioka A, Nishio KM, Shima M: Thrombelastgram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII. Haemostasis 26:139-142, 1996 (suppl)